Jupiter Endovascular – a medical technology startup developing a new class of endovascular procedures using Endoportal Control to bring the precision and control of direct surgical access to catheter-based interventions – announced that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a major participant in the round that included participation from multiple strategic investors. This funding round will be used to support the company’s upcoming pivotal trial for Pulmonary Embolism and the development of additional Endoportal Control technology clinical applications.
The company appointed Carl J. St. Bernard as Jupiter Endovascular’s Chief Executive Officer. St. Bernard – an industry veteran with advanced medical technology leadership experience – joins Jupiter from Alta Biomaterials, where he held the role of President and CEO. And he has over 30 years of experience in the life sciences arena and has held senior executive positions at CeloNova BioSciences, Tryton Medical, Johnson & Johnson Vision, LifeCell, Cordis, and GE Healthcare. He is also an AdvaMed board director.
KEY QUOTES:
“For decades, the field of catheter-based therapies has been limited by the technological constraints of catheters that lose stability and control within the anatomy. Jupiter Endovascular has developed a revolutionary approach with the potential to overcome these constraints by providing clinicians the precision and control of a surgical approach while maintaining the minimally invasive profile of an endovascular procedure. This novel approach may address a significant unmet clinical need in patients with disease residing in complex cardiovascular anatomies, such as the pulmonary arteries.”
- Kate Garrett, Managing Partner at Sonder Capital
“I am very excited to join the Jupiter Endovascular team. The Endoportal Control technology, which leverages Jupiter’s unique and exclusive intellectual property to create a catheter-based device that flexibly navigates through a patient’s vasculature before fixing into a stable position, is designed to give interventionalists the confidence and support they need to deliver a prescribed cardiovascular therapy. This represents a generational advance in technology with the potential to revolutionize the treatment of millions of patients worldwide. We are thrilled to partner with Sonder Capital and our other highly valued investors as we bring this innovation to the clinic and create the foundation for our entry into the Pulmonary Embolism market and future clinical areas where we see a compelling opportunity for Endoportal Control to improve the lives and well-being of patients.”
- Carl J. St. Bernard
“We are excited to welcome Carl St. Bernard as the CEO of Jupiter Endovascular. Carl brings a wealth of experience and a proven track record of success in bringing novel technologies and therapies to market. His vision and leadership will be instrumental as the Jupiter team enters this next clinical phase. We are confident that, under Carl’s guidance, Jupiter Endovascular will address a significant clinical need that has remained unmet for decades.”
- Jay Watkins, Co-Chair and Partner at Sonder Capital
